The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 23, 2014
Filed:
Mar. 15, 2007
Jose Maria Cid-nunez, Toledo, ES;
Jose Ignacio Andres-gil, Toledo, ES;
Andres Avelino Trabanco-suarez, Toledo, ES;
Julen Oyarzabal Santamarina, Toledo, ES;
Frank Matthias Dautzenberg, Beerse, BE;
Gregor James Macdonald, Beerse, BE;
Shirley Elizabeth Pullan, Beerse, BE;
Robert Johannes Lutjens, Geneva, CH;
Guillaume Albert Jacques Duvey, Geneva, CH;
Vanthea Nhem, Corsier, CH;
Terry Patrick Finn, Geneva, CH;
Gagik Melikyan, Manoukian, YE;
Vincent Mutel, Geneva, CH;
Hassan Julien Imogai, Geneva, CH;
Jose Maria Cid-Nunez, Toledo, ES;
Jose Ignacio Andres-Gil, Toledo, ES;
Andres Avelino Trabanco-Suarez, Toledo, ES;
Julen Oyarzabal Santamarina, Toledo, ES;
Frank Matthias Dautzenberg, Beerse, BE;
Gregor James MacDonald, Beerse, BE;
Shirley Elizabeth Pullan, Beerse, BE;
Robert Johannes Lutjens, Geneva, CH;
Guillaume Albert Jacques Duvey, Geneva, CH;
Vanthea Nhem, Corsier, CH;
Terry Patrick Finn, Geneva, CH;
Gagik Melikyan, Manoukian, YE;
Janssen Pharmaceuticals, Inc., Titusville, NJ (US);
Addex Pharma S.A., Geneva, CH;
Abstract
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 ('mGluR2') which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.